Mohammed Al-Yafi, MD
Cardiovascular Disease · Lafayette, INNPI 1639510753
Payments from drug & device makers
Across 203 payments — averaging $127.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$13K
- Medtronic$6K
- Abbott$5K
- Boston Scientific$1K
- Sanofi-aventis U.S. LLC$250
- Biosense Webster, Inc.$232
- plus $380 from 7 others
What the payments were for
- Travel & lodging$18,02869%
- Food & beverage$7,84530%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 76 | $12,925 |
| Medtronic(2 entities) | 53 | $6,000 |
| Abbott | 38 | $5,071 |
| Boston Scientific | 12 | $1,086 |
| Sanofi-aventis U.S. LLC | 2 | $250 |
| Biosense Webster, Inc. | 5 | $232 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $146 |
| Philips North America LLC | 1 | $135 |
| Elutia, Inc. | 3 | $30 |
| Johnson & Johnson | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Terumo Medical Corporation | 1 | $16 |
| Acutus Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sentus$2,388
- Edora$2,354
- Acticor$2,354
- Solia$2,227
- BioMonitor$2,227
- AVEIR$2,208
- Plexa$1,607
- Acticor 7 VR-T DX$1,479
- Edora 8 DR-T$1,479
- Rivacor 7 DR-T$1,479
- ViewMate Intracardiac Echo$1,188
- AURORA EV-ICD MRI SURESCAN$833
- ENSITE PRECISION$796
- Rivacor$748
- EMBLEM MRI S-ICD$645
- EVERA MRI XT DR SURESCAN$386
- Micra$366
- EnSite Velocity System Mapping D$162
- (9124) LM Undivided$135
- GENERAL TACHY$125
How this compares
$25,944 in reported general payments places this provider in the 80th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 17 | $263 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Lafayette
- Steven SteinhublLafayette$2.4M
- John McGintyRichmond$3.7M
- Ravi BhagwatMunster$2.2M
- Mohan KesaniMunster$1.2M
- Vijay MehtaElkhart$925K
- William CollisFort Wayne$842K
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Wail AsfourMunster$736K
- Vijay RaoIndianapolis$706K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.